ENTYVIO
GrowthmAbBLAINTRAVENOUSINJECTABLE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
6/8 — Strong
ENTYVIO by Takeda is α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (madcam-1) and inhibits the migration of memory t-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Approved for immune checkpoint inhibitor-related colitis. First approved in 2024.
ENTYVIO (vedolizumab) is a monoclonal antibody that selectively blocks α4β7 integrin, preventing memory T-lymphocytes from migrating into inflamed gastrointestinal tissue. It is approved for immune checkpoint inhibitor-related colitis and HIV infection, delivered via intravenous injection. The mechanism is gut-selective, avoiding systemic immunosuppression by not inhibiting α4β1 or αEβ7 integrins, positioning it as a targeted therapy in a crowded immunomodulatory landscape.
$0.1BPart D
Mechanism of Action
α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit function of the…
Worked on ENTYVIO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.